HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ellis, J. M. Search for Related Content PubMed PubMed Citation Articles by Ellis, J. M.

From Neuroscience Research of the Berkshires in Pittsfield, Mass.

Address correspondence to Jay M. Ellis, DO, Director, Neuroscience Research of the Berkshires, 100 Wendell Ave, Pittsfield, MA 01201-6941.E-mail: IMdocjay{at}aol.com

Dementia associated with probable Alzheimer's disease (AD) is one of the most common types of dementia. Patients with AD often have cholinergic deficits in association with the disease. The cholinesterase inhibitors donepezil hydrochloride, galantamine hydrobromide, and rivastigmine tartrate are the current mainstays of symptomatic treatment for patients with AD. In clinical trials for all three agents, beneficial effects on standard measures of cognitive and global function have been observed in patients with mild to moderate AD. Although none of the cholinesterase inhibitors has been approved for treatment of patients in advanced stages of AD, all three agents have had beneficial cognitive effects among patients with less severe forms of the disease. The author provides information on recommended dosing for all three medications, noting that cholinesterase inhibitors must be titrated carefully. When administered with caution, galantamine, rivastigmine, and donepezil are generally well-tolerated pharmacologic treatment options. The author notes that, after patients and their caregivers understand that no change in status is considered an "improvement" and a desirable clinical outcome for patients with AD, if no benefits are achieved with the use of one cholinesterase inhibitor, switching to another medication in this class might be beneficial. The author further suggests that the benefits found in cholinesterase inhibitors for patients with AD might also be applicable to patients with other types of dementia such as vascular dementia and dementia with Lewy bodies as cholinergic deficits have been reported in association with these types of dementia as well.

This article has been cited by other articles:

				A. Bekker, M. Haile, K. Gingrich, L. Wenning, A. Gorny, D. Quartermain, and T. Blanck Physostigmine Reverses Cognitive Dysfunction Caused by Moderate Hypoxia in Adult Mice Anesth. Analg., September 1, 2007; 105(3): 739 - 743. [Abstract] [Full Text] [PDF]

				E. Groner, Y. Ashani, D. Schorer-Apelbaum, J. Sterling, Y. Herzig, and M. Weinstock The Kinetics of Inhibition of Human Acetylcholinesterase and Butyrylcholinesterase by Two Series of Novel Carbamates Mol. Pharmacol., June 1, 2007; 71(6): 1610 - 1617. [Abstract] [Full Text] [PDF]

				J. L. Whitwell, S. D. Weigand, M. M. Shiung, B. F. Boeve, T. J. Ferman, G. E. Smith, D. S. Knopman, R. C. Petersen, E. E. Benarroch, K. A. Josephs, et al. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease Brain, March 1, 2007; 130(3): 708 - 719. [Abstract] [Full Text] [PDF]